The principal findings of our study included the observation that in T1DM patients, HBOT downregulates the iNOS activity/expression by decreasing phosphorylation of ERK1/2 and Akt followed by a decreased activation of NFκB. For this study, we have used HBOT as a medical treatment for T1DM patients with the developed peripheral arterial disease, with the purpose to reduce inflammation and to promote microcirculation. This evidence concerns the gene NFKB1 and peripheral arterial disease.